Introduction to IRB

The Institute for Research in Biotherapy (IRB) associates the University Hospital of Montpellier (CHU Montpellier), the INSERM and the University Montpellier I (UM1).

The aim of the IRB is to develop cell or biological drugs in the field of regenerative medicine.

IRB provides a complete chain of expertise associating fundamental research laboratories, hospital biology departments, and private companies. IRB comprises 6 INSERM research laboratories hosting scientific teams after evaluation by AERES (http://www.aeres-evaluation.fr/- and INSERM.

The availability of human cells or tissues with all ethical rules through the university hospital, the close association with Montpellier fundamental research institutes, and the hosting of private companies are major criteria to attract high level scientists, to create new tools in biotherapy, to provide a high level training to students, and to create employment.

IRB gathers up to 130 people (90 academic and 40 private company people) in a 2874 m2 building containing 6 INSERM fundamental research laboratories, 4 CHU translational research laboratories, and 5 laboratories for private companies around common technical platforms providing key technologies for state-of-the-art biotherapy research. IRB is embedded in the large "Biology and Pathology Network" that gathers all hospital laboratories with common management of human and financial resources. IRB is located in direct proximity to the Unit for Cell and Gene Therapy, the Department for Clinical Hematology and Biotherapy and the Clinical Investigation Center. The INSERM "Institute of Neurosciences is also closely located to the IRB on the Hopital St. Eloi Campus and provides access to a common animal facility and bioimaging facilities that can be accessed through the Montpellier RIO imaging network (MRI). IRB has a direct access to the University of Sciences and techniques of Montpellier (UM2) that is going to merge with Universities Montpellier I and III to form a unique University of Montpellier South of France (UMSF).
(http://www.campus-montpellier.fr).

Director : Professor Bernard KLEIN,
bernard.klein@inserm.fr or b-klein@chu-montpellier.fr

 

1. IRB strategy
2. Scientific and medical projects
3. Direction, departments, scientific committee and organization
4. INSERM units, R&D, CHU laboratories, technical platforms
5. Private companies
6. Training
7. Publications, patents and clinical trials
8. Partners

IRB presentation can be obtained as a pdf file :

IRB presentation English.pdf


Technical platforms opened to public or private laboratories :
  Microarray Core facility
  Laboratory of Monitoring of Novel Therapeutics
  Stem Cell Laboratory
  Regional Cytometry Platform - Montpellier Rio-Imaging
  Regional Proteomic Platform

Unit for cellular and Gene therapy

Center for Clinical Investigation in Biotherapy.

Department of Clinical Hematology and Biotherapy

 

With the financial support from the Région Languedoc-Roussillon and the Agglomération Montpellier